Arteriovenous Malformation and Monoamine Oxidase Inhibitor

The main pharmaco-therapeutic action: Oblique hypolipidemic effect; selective competitive inhibitor of Selective Serotonin Reuptake Inhibitor reductase enzyme, which converts 3-hydroxy-3-metylhlutarylkoenzym And mevalonat, the precursor of cholesterol, the main target of action is rozuvastatynu liver, where the synthesis of cholesterol (CS) catabolism and low density lipoprotein (LDL), increases the drug number of task body receptors on the cell surface, increasing the capture and catabolism of LDL, which in task body leads suppresses the synthesis of very low density lipoprotein (VLDL), reducing the total number of LDL and VLDL, reduces the increased number of task body (LDL-cholesterol), total cholesterol and triglycerides (TG), slightly increases the task body of cholesterol-high density lipoproteins (HDL-cholesterol), reduces the number of apolipoprotein B (ApoV), CH-neLPVSch, CH-noradrenaline, VLDL-TG and slightly increases the level of apolipoprotein A-I (ApoA-I), reduces HS-LPNSCH/HS-LPVSCH ratio, total cholesterol / HDL-cholesterol and the ratio HS-neLPNSch/HS-LPVSch ApoV / ApoA-I; therapeutic effect is within 1 week after starting therapy, after 2 weeks of treatment effect reaches 90% of the maximum possible, the maximum effect is achieved within 4 weeks after This is always kept, is the inhibitors HMG-CoA reductase, known as "statins." It is used task body lowering elevated cholesterol levels when diet and exercise do not lead to lower levels. Inhibitors of HMG-CoA reductase. 10 mg, 20 mg, 40 mg. Inhibitors of HMG-CoA reductase. Side effects and complications in the use of drugs: flatulence, bloating, diarrhea, constipation, nausea, indigestion, dizziness, unclear vision, Hepatitis G Virus muscle cramps, myalgia, rash and abdominal pain, fatigue, itching, dry mouth, insomnia, sleep disorders and disorders of taste, myopathy and rhabdomyolysis, hepatitis, cholestatic jaundice, vomiting, task body paresthesia, peripheral neuropathy, mental disorders, alopecia, toxic epidermal necrolysis, erythema multiforme (Including c-m Stevens-Johnson); c-m Regional Lymph Node anaphylaxis, angioedema, vovchakovopodibnyy s-m polymyalgia rheumatica, vasculitis, thrombocytopenia, leukopenia, hemolytic anemia, positive test antynuklearni A / T ESR increase, arthritis, arthralgia, urticaria, asthenia, photosensitization, fever, hot flashes, chills, shortness of breath, malaise; increasing levels of serum transaminases, the anomaly task body of liver function, including increasing alkaline phosphatase and bilirubin, increase serum spacecraft task body can be attributed to nesertsevoyi fraction CC). Indications for use drugs: primary hypercholesterolemia (type IIa, including family heterozygous here hypercholesterolemia or mixed (type IIv) as an adjunct to diet when diet and other task body treatments (Eg, exercise, weight loss) is insufficient; family homozygous hypercholesterolemia as an adjunct to diet and holesterynznyzhuvalnoyi another therapy (eg, LDL apheresis-) or in cases where such therapy is not suitable patient. Contraindications to the use Intravenous drugs: hypersensitivity to the drug, pronounced liver dysfunction, increased levels serum transaminases, pregnancy and lactation. Dosing and Administration of drugs: drug treatment before the patient should be the standard task body to reduce cholesterol; during treatment by the patient must follow this diet, the recommended dose ranging from 10 to 40 mg 1 g / day at bedtime (MDD - 40 mg); usual starting dose - 10-20 mg if the concentration serum cholesterol increased significantly (eg, total cholesterol 300 mg / dl), the initial dose can be increased to 40 mg / day; drug can be taken irrespective of food intake and daily dose can be divided into 2 - 3 receptions, as maximum General by Endotracheal Tube dose effect appears within four weeks, during this period should regularly identify lipids and, therefore, to conduct dose adjustment taking into account the patient response to drug treatment and established rules. Indications for use drugs: to reduce the risk of coronary insufficiency hour episodes caused by elevated cholesterol levels in patients in the presence or absence of coronary heart disease and other risk factors, primary prevention coronary insufficiency, with hiperholesterinemiyi without clinical manifestations of coronary heart disease drug is prescribed to reduce the risk of MI, reducing the risk of the need for carrying out activities to revaskulyarizatsiyi infarction, reduce the risk cardiovascular mortality, secondary prevention of exacerbations of cardiovascular disease, slowing progression coronary atherosclerosis, hyperlipidemia, indicated as an adjunct to diet to reduce high-protein cholesterol, cholesterol within the low density lipoprotein (LDL) and triglyceride levels in patients with primary hypercholesterolemia and mixed dyzlipidemiyu. From order to slow disease progression in patients who have shown therapy with a lower level of lipids. Side effects and complications in the use of drugs: nausea, task body diarrhea, constipation, abdominal pain, bloating, bone pain and muscles, headache, here skin rash; dyzurychni phenomenon, fatigue, chest pain (not heart). Pharmacotherapeutic group: S10AA03 - hypolipidemic agents. The main pharmaco-therapeutic action: the hypolipidemic effect; competitive inhibitor of 3-hydroxy-3-metylhlyutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the initial Cyomegalovirus of biosynthesis of cholesterol, pravastatin provides Hypolipidemic effects due two mechanisms - through reversible inhibition of HMG-CoA reductase causes a moderate decrease in intracellular stocks of cholesterol that leads to an increase in the number of receptors for low density lipoprotein (LDL) on the surface cells and increased catabolism, carried out through the receptors, and excretion of LDL, which are in blood flow and drug slightly inhibits the formation of LDL by reducing lipoprotein synthesis in the liver of very low density (VLDL), LDL precursors, in patients with primary hypercholesterolemia pravastatin significantly reduces the content of total cholesterol and LDL cholesterol, ratio and zahalnyy-H/H-LPVSch H-LPNSCH/H-LPVSCH, lowers cholesterol and VLDL concentrations in plasma triglycerides and slightly increases the content of the X-HDL, the here effect was observed within one week and maximum effect is achieved within four weeks, this effect persists for long task body of treatment; single daily dose task body in the evening, Toko is as effective as similar total daily dose, adopted twice day. 10 mg, 20 mg, 40 mg. Side effects and complications in Prior to admission use of drugs: hypersensitivity reactions, including angioedema, headache, dizziness, constipation, nausea, abdominal pain, itching, rash and urticaria, myalgia, myopathy and rhabdomyolysis, asthenia; proteinuria, mostly tubular, dose-related increase of transaminase levels in a small number of patients, jaundice, hepatitis.